Rezolute, Inc. (RZLT)


+0.02 (+2.47%)
Symbol RZLT
Price $0.8597
Beta 2.012
Volume Avg. 0.04M
Market Cap 34.066M
Shares () -
52 Week Range 0.72-2.9
1y Target Est -
DCF Unlevered RZLT DCF ->
DCF Levered RZLT LDCF ->
ROE -46.29% Strong Sell
ROA -50.01% Strong Sell
Operating Margin -
Debt / Equity 2.26% Neutral
P/E -0.78
P/B 0.43 Neutral


Consensus EPS

Upgrades & Downgrades

Latest RZLT news

Mr. Nevan Charles Elam J.D.
NASDAQ Capital Market

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.